Research progress of bispecific antibody in hematologic neoplasms therapy

Immunotherapy as a new oncotherapy method, there is a large number of literature was carried out from basic and clinical studies. As artificial antibodies contain two specific antigen binding sites, bispecific antibodies (BsAb) can induce effector cells targeted kill tumor cells with good prospects for clinical application, such as anti CD3/CD19 BsAb and anti CD33/CD3 BsAb. And BsAb has become a research hotspot in immunotherapy of hematologic neoplasms. The author intends to review the research progress of BsAb in the treatment of hematologic neoplasms from the aspects of basic research and clinical trials, in order to explore the potential application of BsAb in hematologic neoplasms. Key words: Antibodies, bispecific; Hematologic neoplasms; Immunotherapy